Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
Abiraterone, Androgen, animal, announced, ARAT, arising, arm, Bach, CanSEEKTM, cap, carved, castrate, centrally, chain, chemotherapy, clearance, criteria, crossover, demonstrated, DGCL, dose, dosimetry, enabling, endpoint, Enzalutamide, Europe, Family, FAP, fibroblast, foot, fourth, ft, fulfill, half, human, IND, inhibitor, intrinsic, Invention, Investigational, isotope, Kingdom, large, leveraged, mCRPC, met, metastatic, ninety, North, ORR, OS, overlooked, PK, Prodrug, prostate, protocol, radiation, radiographic, radioisotope, randomization, randomized, rapid, rare, readout, reduction, refuse, regression, regular, resilient, resistant, resolve, secondary, ship, sq, square, tumor, UK, unique, visit, volume, warhead
Removed:
broad, covenant, guaranteed, inability, reduced
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view